A pinboard by
Oluwaseun Adeyanju

Lecturer, Afebabalola University


Oestrogen deficiency-induced cardiometabolic disorder

Globally, cardiometabolic disorder (CMD) is assuming an increasing role as a major cause of morbidity and mortality. It identifies a cluster of metabolic disorders including visceral adiposity, insulin resistance (IR), hyperglycemia, dyslipidemia and hypertension, that occur together and place affected individuals at up to 2 times higher risk of a major cardiovascular event, 3 times higher risk of chronic renal insufficiency, more than 4 times higher danger of type 2 diabetes mellitus, incidence of congestive heart failure and cardiovascular mortality. Gender differences in the development of cardiovascular disease (CVD) are well documented in both human and animal experimental studies. The incidence of CVD among women increases sharply during menopause which is thought to result in part from the deficient endogenous oestrogen and its associated cardioprotective effects. A loss of ovarian function is associated with increased fat, along with metabolic pathologies including insulin resistance (IR) and type 2 diabetes (T2D). The fact that increasing numbers of women, who will spend the second half of their lives in a state of oestrogen deficiency, expect longer life spans requires an understanding of the pathologies of metabolic diseases associated with oestrogen deficiency observed in them. Mineralocorticoid Receptor (MR) activation has been implicated in the pathogenesis of the components of Cardiometabolic Disorder (CMD), an enormously growing public health problem made up of interconnected and heterogenous disorders including IR, dyslipidaemia and endothelial dysfunction. Hence, factors or intervention that could influence the development of CMD in postmenopausal women who are in a state of oestrogen deficiency, will be of great public health importance.